by What is the Influenza Vaccine Market Size?
The global influenza vaccine market size was valued at USD 9.02 billion in 2025 and is projected to grow from USD 9.73 billion in 2026 to approximately USD 19.19 billion by 2035, registering a CAGR of 7.84% during the forecast period from 2026 to 2035.
Get Sample : https://www.precedenceresearch.com/sample/3637
Influenza Vaccine Market Key Takeaways
- The global influenza vaccine market was valued at USD 9.02 billion in 2025.
- It is projected to reach USD 19.19 billion by 2035.
- The influenza vaccine market is expected to grow at a CAGR of 7.84% from 2026 to 2035.
- North America contributed more than 47% of the market share in 2025.
- Asia-Pacific is estimated to witness the fastest CAGR between 2026 and 2035.
- By vaccine type, the quadrivalent segment has held the largest market share of 65% in 2025.
- By vaccine type, the trivalent segment is anticipated to grow at a remarkable CAGR of 10.1% between 2026 and 2035.
- By technology, the egg-based segment generated over 69% of the market share in 2025.
- By technology, the cell culture segment is expected to expand at the fastest CAGR over the projected period.
- By age group, the pediatric segment held the largest market share of 59% in 2025.
- By age group, the adult segment is expected to expand at the fastest CAGR over the projected period.
- By route of administration, the nasal spray segment generated over 53% of the market share in 2025.
- By route of administration, the injection segment is expected to expand at the fastest CAGR over the projected period.
Market Overview
The influenza vaccine market focuses on the development, production, and distribution of vaccines designed to protect against influenza viruses. The market is witnessing steady growth due to increasing global health initiatives, rising seasonal influenza outbreaks, and growing demand for preventive healthcare solutions. Expanding government immunization programs and increasing public awareness regarding influenza-related complications are further supporting market expansion.
Leading companies are investing heavily in vaccine development, advanced production technologies, and stronger distribution networks to address the growing global vaccination demand. In addition, continuous research and development activities are enhancing vaccine effectiveness and supporting protection against rapidly evolving influenza strains, contributing to the long-term growth and dynamism of the market.
Market Scope
| Report Coverage | Details |
| Market Size by 2035 | USD 19.19 Billion |
| Market Size in 2025 | USD 9.02 Billion |
| Market Size in 2026 | USD 9.73 Billion |
| Growth Rate from 2026 to 2035 | CAGR of 7.84% |
| Largest Market | North America |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
Regional Insights
What is the U.S. Influenza Vaccine Market Size?
The U.S. influenza vaccine market size is valued at USD 2.98 billion in 2025 and is expected to reach USD 6.46 billion by 2035, growing at a CAGR of 8.04% from 2026 to 2035.
What Factors Drive the Dominating Position of North America in the Influenza Vaccine Market?
North America dominated the influenza vaccine market with the largest revenue share of 47% in 2025. The region’s growth is primarily driven by its well-established healthcare infrastructure, strong government support, and extensive immunization programs. Increasing public awareness regarding influenza prevention and the importance of seasonal vaccination continues to support consistent market demand across the region.
In addition, technological advancements such as digital vaccination monitoring systems and improved vaccine distribution networks are gaining traction in North America. Strategic collaborations between pharmaceutical companies and research institutions are also accelerating the development of next-generation influenza vaccines, reinforcing the region’s strong commitment to public health and disease prevention.
North America: U.S. Influenza Vaccine Market Trends
In the U.S., demand is rising due to increasing public awareness of flu risks and more aggressive government vaccination campaigns. There’s a clear shift toward quadrivalent vaccines that protect against four flu strains, as manufacturers scale up production to meet broader coverage needs. Breakthroughs in mRNA technology are reshaping the market, with companies pushing forward next-generation, more effective flu shots.
How is the Rapid Growth of Asia Pacific in the Influenza Vaccine Market?
Asia-Pacific is expected to witness the fastest growth in the influenza vaccine market during the forecast period. The regional market is being driven by increasing healthcare awareness, expanding immunization initiatives, and rising government focus on disease prevention. Rapid population growth in emerging economies is further boosting the demand for influenza vaccines, encouraging significant investments in vaccine production and distribution infrastructure.
The region is also experiencing increased collaborations for technology transfer and localized vaccine manufacturing to strengthen supply capabilities. In addition, tailored vaccination programs, public health campaigns, and supportive government initiatives are promoting a proactive approach toward influenza prevention, reflecting the rapidly evolving healthcare landscape across Asia-Pacific.
What are the Government Initiatives for the Influenza Vaccine Market?
- United States: The CDC increased its annual influenza vaccination drives and sponsored influenza immunization drives throughout the nation for children, adults, and high-risk groups.
- China: China stepped up its immunization efforts for its population by raising awareness regarding the influenza vaccine and providing seasonal vaccination programs through public health initiatives.
- Europe: The European Commission backed influenza preparation plans through coordinated vaccine purchases and pandemic influenza stockpile programs.
- UAE: The UAE Ministry of Health introduced needle-free nasal influenza vaccines to promote greater accessibility and participation in vaccinations.
Major Key Players
- BiondVax Pharmaceuticals Ltd.
- Novavax, Inc.
- Bharat Biotech
- Johnson & Johnson
- MedImmune, LLC (AstraZeneca)
- FluGen
- Mitsubishi Tanabe Pharma Corporation
- Emergent BioSolutions
- Sinovac Biotech Ltd.
- Bio Farma
Recent Developments
- In May 2026, the SNIFFLES study was initiated by Murdoch Children’s Research Institute in Victoria to compare FluMist nasal spray flu vaccine with regular injectable influenza vaccines among children. The objective of this research was to analyze the immune response and develop strategies for pediatric influenza vaccinations using needle-free flu vaccines. (Source: https://www.medicalrepublic.com.au)
- In October 2025, Sanofi reported a superior protection from its high-dose influenza vaccine for older adults against hospitalization compared to standard-dose. These dose are results in reduced hospital admissions of patients dealing with laboratory-confirmed influenza. (Source: https://www.sanofi.com)
- In July 2025, GlaxoSmithKline plc (GSK) began shipping of influenza vaccine doses, namely FLULAVAL (Influenza Vaccine) and FLUARIX (Influenza Vaccine), for the 2025-26 flu season. Company is continues its support for seasonal flu immunization in the U.S. (Source: https://us.gsk.com)
Segments Covered in the Report
By Vaccine Type
- Quadrivalent
- Trivalent
By Technology
- Egg-based
- Cell culture
By Age Group
- Pediatric
- Adult
By Route of Administration
- Injection
- Nasal Spray
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Check this Report too : Breast Biopsy Devices Market
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/3637
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344
- Influenza Vaccine Market Size to Attain USD 19.19 Bn by 2035 - May 26, 2026
- Autoinjectors Market Size to Touch USD 414.66 Bn by 2035 - May 25, 2026
- Breast Biopsy Devices Market Size to Touch USD 1.70 Bn By 2035 - May 21, 2026
